Clinical trial No longer in our active list Phase 3 Interventional Ages 18 to 100

Evaluating ianalumab with corticosteroids for treating primary immune thrombocytopenia

Official title: A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1)

Run by Novartis · NCT05653349 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if a new drug called ianalumab can help adults with primary immune thrombocytopenia maintain healthy platelet levels when used with standard corticosteroids.

More Primary Immune Thrombocytopenia (ITP) trials Research outlook What's coming for Immune thrombocytopenia: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 100 Years
SexAll
Enrollment225 (estimated)
SponsorNovartis
Industry-sponsored
Drugs / interventionsrituximab, ianalumab
Locations152 sites (Yuma, Arizona and 151 other locations)
Trial IDNCT05653349 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older diagnosed with primary ITP within the last three months and having a platelet count below 30 G/L.

Probably not a fit

Patients with Evans syndrome, life-threatening bleeding, or those who have previously undergone ITP treatments other than corticosteroids or IVIG may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 clinical trial investigates the efficacy and safety of two doses of ianalumab compared to a placebo in adult patients with primary immune thrombocytopenia (ITP) who are receiving first-line corticosteroid treatment. Participants will be randomly assigned to receive either ianalumab or placebo alongside standard corticosteroids, with the primary goal of maintaining a platelet count of at least 30 G/L. The study will include a screening period followed by a treatment phase, and participants will be monitored for efficacy and safety outcomes during a follow-up period.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with primary immune thrombocytopenia, potentially improving platelet counts and reducing the need for more invasive treatments.

How similar studies have gone: Other studies have shown promising results with similar approaches targeting B-cell depletion in ITP, suggesting potential for success in this trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Signed informed consent prior to participation in the study.
* Male or female participants aged 18 years and older on the day of signing informed consent
* Primary ITP diagnosed within 3 months before initiating first-line ITP therapy (corticosteroids, IVIG)
* Platelet count below 30 G/L before starting any first-line ITP therapy (corticosteroids, IVIG)
* Response (platelet count \>=50 G/L) to corticosteroids (+/- IVIG) at any time prior to randomization. Note: Platelet count measured within 7 days of platelet transfusion will not be considered as response.

Key Exclusion Criteria:

* Evans syndrome or any other cytopenia (patients with low grade anemia related to bleeding or iron deficiency are eligible)
* Current life-threatening bleeding
* Previous ITP treatment, including splenectomy, except for corticosteroids and/or IVIG initiated as first-line therapy for up to 28 days before randomization and rescue corticosteroids and/or IVIG given prior to confirmed diagnosis of primary ITP .
* Prior use of B-cell depleting therapy (e.g., rituximab).
* Absolute neutrophil count below 1.0 G/L at randomization
* Participants with concurrent coagulation disorders and/or receiving anti-platelet or anticoagulant medication with an exemption of low dose of acetylsalicylic acid

Other protocol-defined Inclusion/Exclusion may apply.

Where it's running

  • Yuma Regional Medical Center
    Yuma, Arizona, United States
    Recruiting
  • Community Cancer Institute
    Clovis, California, United States
    Recruiting
  • Compassionate Care Res Group Inc
    Fountain Valley, California, United States
    Recruiting
  • University of Colorado Anschutz
    Aurora, Colorado, United States
    Recruiting
  • Napa Research
    Margate, Florida, United States
    Recruiting
  • Uni of Chi Medi Ctr Hema and Onco
    Chicago, Illinois, United States
    Recruiting
Show 44 more locations
  • Oncology Care Associates
    Bethesda, Maryland, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts, United States
    Recruiting
  • Michigan Center of Medical Research
    Farmington Hills, Michigan, United States
    Recruiting
  • Mayo Clinic Rochester
    Rochester, Minnesota, United States
    Recruiting
  • Metro Minnesota CCOP
    Saint Louis Park, Minnesota, United States
    Recruiting
  • St Vincent Frontier Cancer Center
    Billings, Montana, United States
    Recruiting
  • Inspira Medical Cent Mullica Hill
    Mullica Hill, New Jersey, United States
    Recruiting
  • Clinical Research Alliance
    Lake Success, New York, United States
    Recruiting
  • Hematology Oncology Association of Rockland
    Nyack, New York, United States
    Recruiting
  • Cleveland Clinic Foundation
    Cleveland, Ohio, United States
    Recruiting
  • STAT Research Inc
    Dayton, Ohio, United States
    Recruiting
  • INTEGRIS Cancer Institute of Oklahoma
    Oklahoma City, Oklahoma, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania, United States
    Recruiting
  • Rhode Island Hospital
    Providence, Rhode Island, United States
    Recruiting
  • Texas Oncology-Baylor Res Ins
    Dallas, Texas, United States
    Recruiting
  • Texas Oncology
    McAllen, Texas, United States
    Recruiting
  • Mays Cancer Ctr Uthsa Mdacc
    San Antonio, Texas, United States
    Recruiting
  • Community Cancer Trials of Utah
    Ogden, Utah, United States
    Recruiting
  • Novartis Investigative Site
    Bahia Blanca, Buenos Aires, Argentina
    Recruiting
  • Novartis Investigative Site
    Caba, Buenos Aires, Argentina
    Recruiting
  • Novartis Investigative Site
    Caba, Buenos Aires, Argentina
    Recruiting
  • Novartis Investigative Site
    Ciudad Autonoma de Bs As, Buenos Aires, Argentina
    Recruiting
  • Novartis Investigative Site
    Tucuman, San Miguel De Tucuman, Argentina
    Recruiting
  • Novartis Investigative Site
    Buenos aires, Argentina
    Recruiting
  • Novartis Investigative Site
    Cordoba, Argentina
    Recruiting
  • Novartis Investigative Site
    Canberra, Australian Capital Territory, Australia
    Recruiting
  • Novartis Investigative Site
    Wooloongabba, Queensland, Australia
    Recruiting
  • Novartis Investigative Site
    Clayton, Victoria, Australia
    Recruiting
  • Novartis Investigative Site
    Melbourne, Victoria, Australia
    Recruiting
  • Novartis Investigative Site
    Innsbruck, Tyrol, Austria
    Recruiting
  • Novartis Investigative Site
    Wien, Austria
    Recruiting
  • Novartis Investigative Site
    Brasschaat, Belgium
    Recruiting
  • Novartis Investigative Site
    Brugge, Belgium
    Recruiting
  • Novartis Investigative Site
    Leuven, Belgium
    Recruiting
  • Novartis Investigative Site
    Roeselare, Belgium
    Recruiting
  • Novartis Investigative Site
    Plovdiv, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Sofia, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Sofia, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Beijing, Beijing, China
    Recruiting
  • Novartis Investigative Site
    Chongqing, Chongqing, China
    Recruiting
  • Novartis Investigative Site
    Guangzhou, Guangdong, China
    Recruiting
  • Novartis Investigative Site
    Shenzhen, Guangdong, China
    Recruiting
  • Novartis Investigative Site
    Luoyang, Henan, China
    Recruiting
  • Novartis Investigative Site
    Zhengzhou, Henan, China
    Recruiting

+102 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.